Background/aim: The incidence of biliary tract cancers (BTC), including cholangiocarcinoma and gallbladder cancer, has been increasing worldwide. Approximately 70% of BTC patients have advanced disease at diagnosis, leading to a poor survival rate. Recent clinical trials have demonstrated that the addition of immune checkpoint inhibitors, such as durvalumab or pembrolizumab, to gemcitabine plus cisplatin chemotherapy significantly improves survival rates, making triple therapy the current standard for first-line treatment of BTC.
View Article and Find Full Text PDFIntroduction: Although neuroendocrine neoplasms (NENs) have a good prognosis, distant metastasis remains a crucial prognostic factor. Survivin, a tumor-associated antigen, is overexpressed in several solid tumors, indicating poor prognosis. We aimed to evaluate the clinical significance and role of survivin as a therapeutic target for NEN.
View Article and Find Full Text PDFMicrobiol Resour Announc
December 2024
is one of the major clinical anaerobic bacteria belonging to the family . Herein, we report the complete genome sequence of a clinical isolate of new species obtained from equine bronchial lavage fluid in Japan. The genome comprised a circular chromosome with a length of 2,948,037 bp.
View Article and Find Full Text PDF